

SYNTHESIS OF COMPOUND X, A NON-STEROIDAL CONSTITUENT OF  
FEMALE URINE, AND CONGENERS

M.B. Groen<sup>\*</sup> and J. Leemhuis


Organon Scientific Development Group

5340 BH Oss, The Netherlands

Summary : The synthesis of trans-(+)- and (-)-3,4-bis [(3-hydroxyphenyl) methyl] dihydro-2-(3H)-furanone (1), a recently discovered constituent of female urine, and some related compounds of biological interest is described.


During gaschromatographic analysis of urinary estrogens<sup>1</sup> Stitch and coworkers observed the persistent occurrence of an unknown component (Compound X)<sup>2</sup>. The periodic excretion of this compound with distinct maxima in the luteal phase of the menstrual cycle and during the first trimester of pregnancy suggested Compound X to have biological significance<sup>2</sup>. Recently the structure of Compound X was shown to be : trans-(+)-3,4-bis [(3-hydroxyphenyl) methyl] dihydro-2-(3H)-furanone (1)<sup>3</sup>. The same substance appears to be excreted by a monkey species (Cercopithecus Aethiopus Pygerythrus)<sup>4</sup>.

The structure of 1 is most intriguing, since it bears a striking resemblance to some of the lignans<sup>5</sup>, a group of natural products occurring in plants, but thus far not encountered in man or animal. Lignans recently have received a great deal of attention because many members show anti-tumour activity<sup>5, 6</sup>, among which compounds 2 and 3<sup>7</sup>. Furthermore, while the resemblance of 1 with the natural estrogens is remote there is some similarity with synthetic non-steroidal estrogens, such as hexestrol (4).



The potential biological activity of 1 prompts us to report its synthesis, which also should be

applicable to lignans with related structure. The diol 6<sup>8</sup>, mp 81–82°C, easily obtained by reduction of the known diester 5<sup>9</sup>, was converted into the monotosylate 7 (1 equiv. of NaH, p-TsCl, THF/HMPA, 20°C, 2h) and hence into the nitrile 8 (KCN, DMSO, 50°C). Hydrolysis of the nitrile with concomitant ring closure (conc. H<sub>2</sub>SO<sub>4</sub>/HOAc/H<sub>2</sub>O 1:10:5, 110°C, 0.5h) produced the monosubstituted lactone 10 in 52% yield (based on 6) as an oil.




The anion of 10 was generated (*i*-Pr<sub>2</sub>NLi, THF/HMPA, -70°C) and alkylated with *m*-methoxybenzyl-bromide (-70 to -50°C) to give 11 (oil) in 70–80% yield. Subsequent demethylation (BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0°C) produced 1, mp 141–143°C, in 80% yield. This material was identical with Compound X of natural origin<sup>2, 3</sup>.

When the lactone 10 was treated successively with aqueous base and acid the unstable hydroxy acid 9 was obtained, which was resolved via its salt with *d*-amphetamine. Acid treatment of the less-soluble diastereomeric salt, obtained by four recrystallizations from ethyl acetate, produced (+)-10,  $[\alpha]_{\text{D}}^{20} = +6.4^\circ$  (*c*=1, CHCl<sub>3</sub>).


From this by the same sequence as described for the racemic compounds (-)-1 was obtained, mp 125–129°C,  $[\alpha]_{\text{D}}^{20} = -38.4^\circ$  (*c*=0.5, CHCl<sub>3</sub>). The optical rotations of (+)-10 and (-)-1 compare favourably with those reported for the closely related lactones 12 ( $[\alpha]_{\text{D}}^{20} = +4.8^{10a}$ ;  $+5.22^{10b}$ ) and 13 ( $[\alpha]_{\text{D}}^{20} = -35^\circ$ <sup>11</sup>) with known absolute configuration. Therefore most likely (-)-1 also has the 3*R*, 4*R* configuration (as depicted in the formula of 1).

Comparison of the specific optical rotation of (-)-1 with those found for samples of Compound X ( $[\alpha]_{\text{D}}^{20} = -5^\circ$  to  $0^\circ$ ) shows that the latter is nearly racemic, the optical purity not exceeding ~13%. This virtually precludes the already unlikely



possibility that Compound X is somehow derived from lignans ingested with the diet, since in nature these occur in the optically pure 3R, 4R form only. While racemization at C-3 might occur such is not the case for the chiral centre at C-4, so that any optical activity present in compounds like 1 should be retained even under rigorous conditions. At the same time the absence of significant optical activity in Compound X suggests that it is not a primary product of biosynthesis, but rather a metabolite of an as yet unknown biologically relevant substance. Therefore some conceivable precursors of natural 1 were synthesized also.

Thus when 11 was refluxed with 25% KOH in 50% aqueous ethanol for three days a mixture of hydroxy acids was obtained. Fractional lactonization<sup>12</sup> gave starting material 11 (30% yield) and its cis-isomer 14 (29% yield). Demethylation of 14 (BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0°C) produced 15, mp 157-158°C, in 70% yield; 200 MHz <sup>1</sup>H-NMR spectrum (CDCl<sub>3</sub>) :



$\delta$  2.68 (m, H at C-4), 2.27 (dd, J= 13.5 & 12) and 2.92 (dd, J= 13.5 & 4, ArCH<sub>2</sub> at C-4), 2.75 (dd, J= 14.5 & 10.5) and 3.21 (dd, J= 14.5 & 4.5, ArCH<sub>2</sub> at C-3), 3.08 (ddd, J= 10.5, 7 & 4.2, H at C-3), 4.00 (ddd, J= 9, 4.5 & 0.7, H at C-5), 4.08 (dd, J= 9.2 & 2, H at C-5), 6.4 - 7.2 (m, 8, aromatic H's).

The <sup>1</sup>H-NMR spectral data of 15 are consistent with an envelope conformation of the lactone ring with the substituent at C-3 in a quasi-equatorial and the one at C-4 in a quasi-axial position<sup>13</sup>. Reduction of 1 (LiAlH<sub>4</sub>, THF, 20°C, 2h) produced the (+)-diol 16, mp 171-173°, 60 MHz <sup>1</sup>H NMR (DMSO-d<sub>6</sub>):  $\delta$  1.87 (m, 2, tertiary H's), 2.44 (m, 4, benzylic H's), 3,3 (d, J= 2.5, 4, 2xCH<sub>2</sub>OH) 6.4-7.1 (m, 8, aromatic H's). Similar reduction of 15 gave the meso-diol 17 as a viscous oil. Among the compounds 15-17 the last compound is the most likely candidate of being a precursor of Compound X, being inherently symmetrical. Investigation of the endocrinological and pharmacological properties of the compounds 1 and 15-17 is under way.

References and notes

1. P.D. Smith and S.R. Stitch, *Clin. Chim. Acta*, 36, 493 (1972)
2. S.R. Stitch, P.D. Smith, D. Illingworth and K. Toumba, *J. Endocrin.* 85, 23 (1980)
3. S.R. Stitch, J.K. Toumba, M.B. Groen, C.W. Funke, J. Leemhuis, J. Vink and G.F. Woods, *Nature*, in print.
4. K.D.R. Setchell, R. Bull and H. Adlercreutz, *J. Steroid Biochem.*, 12, 375 (1980) ;  
H. Adlercreutz, announcement at the 1980 Laurentian Hormone Conference .
5. a) J. Grimshaw in "Rodd's Chemistry of Carbon Compounds", vol. III<sup>d</sup>, 255f.f.,  
Elsevier Scientific Publishing Company, Amsterdam, 1976 ;  
b) M.S. Adjangba, *Bull. Soc. Chim.*, 2344 (1963) ;  
c) W.M. Hearon and W.S. MacGregor, *Chem. Reviews*, 55 957 (1955)
6. a) S.M. Kupchan, R.W. Britton, M.F. Ziegler, C.J. Gilmore, R.J. Restivo and  
R.F. Bryan, *J. Am. Chem. Soc.*, 95, 1335 (1973)  
b) J.L. Hartwell and M.J. Shear, *J. Nat. Cancer Inst.*, 10, 1295 (1950)
7. P.B. McDaniel and R.J. Cole, *J. Pharm. Sci.*, 61, 1992 (1972)
8. This compound is an intermediate for the total synthesis of 7-alkoxymethyl-19-  
norsteroids : F.J. Zeelen and M.B. Groen, to be published
9. J.M. Bruce, D. Creek, K. Dawes, *J. Chem. Soc., C*, 3749 (1971)
10. a) M. Kuhn and A. von Wartburg, *Helv. Chim. Acta* 50, 1546 (1967)  
b) K. Tomioka and K. Koga, *Tetrahedron Letters* 3315 (1979)
11. A.W. Schrecker and J.L. Hartwell, *J. Am. Chem. Soc.*, 76, 4896 (1954)
12. Cf. R.D. Naworth and J.R. Atkinson, *J. Chem. Soc.*, 797 (1938)
13. Reported <sup>1</sup>H-NMR spectral data of 1<sup>3</sup> indicate that in this compound the lactone  
ring has a similar conformation, both substituents now being in a quasi-equatorial  
position

(Received in UK 9 November 1980)